Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Impact of universal health insurance coverage in Thailand on sales and market share of medicines for non-communicable diseases: an interrupted time series study.

Garabedian LF, Ross-Degnan D, Ratanawijitrasin S, Stephens P, Wagner AK.

BMJ Open. 2012 Nov 28;2(6). pii: e001686. doi: 10.1136/bmjopen-2012-001686. Print 2012.

2.

Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis.

Sruamsiri R, Wagner AK, Ross-Degnan D, Lu CY, Dhippayom T, Ngorsuraches S, Chaiyakunapruk N.

BMJ Open. 2016 Mar 17;6(3):e008671. doi: 10.1136/bmjopen-2015-008671.

3.

Why has the Universal Coverage Scheme in Thailand achieved a pro-poor public subsidy for health care?

Limwattananon S, Tangcharoensathien V, Tisayaticom K, Boonyapaisarncharoen T, Prakongsai P.

BMC Public Health. 2012;12 Suppl 1:S6. doi: 10.1186/1471-2458-12-S1-S6. Epub 2012 Jun 22.

4.

Pharmaceutical policies: effects of cap and co-payment on rational use of medicines.

Luiza VL, Chaves LA, Silva RM, Emmerick IC, Chaves GC, Fonseca de Araújo SC, Moraes EL, Oxman AD.

Cochrane Database Syst Rev. 2015 May 8;(5):CD007017. doi: 10.1002/14651858.CD007017.pub2. Review.

PMID:
25966337
5.

Promoting universal financial protection: how the Thai universal coverage scheme was designed to ensure equity.

Tangcharoensathien V, Pitayarangsarit S, Patcharanarumol W, Prakongsai P, Sumalee H, Tosanguan J, Mills A.

Health Res Policy Syst. 2013 Aug 6;11:25. doi: 10.1186/1478-4505-11-25.

6.

Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.

Fang Y, Wagner AK, Yang S, Jiang M, Zhang F, Ross-Degnan D.

Lancet Glob Health. 2013 Oct;1(4):e227-37. doi: 10.1016/S2214-109X(13)70072-X. Epub 2013 Sep 24.

7.

Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.

Fraeyman J, Verbelen M, Hens N, Van Hal G, De Loof H, Beutels P.

Appl Health Econ Health Policy. 2013 Oct;11(5):543-52. doi: 10.1007/s40258-013-0054-9.

PMID:
24062144
8.

Policies and programs to facilitate access to targeted cancer therapies in Thailand.

Sruamsiri R, Ross-Degnan D, Lu CY, Chaiyakunapruk N, Wagner AK.

PLoS One. 2015 Mar 23;10(3):e0119945. doi: 10.1371/journal.pone.0119945. eCollection 2015.

9.

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kösters JP, Vacca C, Machado M, Diaz Ayala DH, Oxman AD.

Cochrane Database Syst Rev. 2014 Oct 16;(10):CD005979. doi: 10.1002/14651858.CD005979.pub2. Review.

PMID:
25318966
10.

Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses.

Leopold C, Zhang F, Mantel-Teeuwisse AK, Vogler S, Valkova S, Ross-Degnan D, Wagner AK.

Int J Equity Health. 2014 Jul 25;13:53. doi: 10.1186/1475-9276-13-53.

11.

Explanation of inequality in utilization of ambulatory care before and after universal health insurance in Thailand.

Yiengprugsawan V, Carmichael G, Lim LY, Seubsman S, Sleigh A.

Health Policy Plan. 2011 Mar;26(2):105-14. doi: 10.1093/heapol/czq028. Epub 2010 Aug 24.

12.

Evaluation of the implementation outcomes of the Essential Medicines System in Anhui county-level public hospitals: a before-and-after study.

Xu S, Bian C, Wang H, Li N, Wu J, Li P, Lu H.

BMC Health Serv Res. 2015 Sep 22;15:403. doi: 10.1186/s12913-015-1073-z.

13.
14.

Healthcare reform in the United States and China: pharmaceutical market implications.

Daemmrich A, Mohanty A.

J Pharm Policy Pract. 2014 Jul 14;7(1):9. doi: 10.1186/2052-3211-7-9. eCollection 2014.

15.

Pharmaceutical policies: effects of cap and co-payment on rational drug use.

Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, Kösters JP, Vernby A.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD007017. doi: 10.1002/14651858.CD007017. Review. Update in: Cochrane Database Syst Rev. 2015;5:CD007017.

PMID:
18254125
16.

Does harmonization of payment mechanisms enhance equitable health outcomes in delivery of emergency medical services in Thailand?

Suriyawongpaisal P, Aekplakorn W, Tansirisithikul R.

Health Policy Plan. 2015 Dec;30(10):1342-9. doi: 10.1093/heapol/czv005. Epub 2015 Mar 21.

PMID:
25797471
17.

Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.

Jirawattanapisal T, Kingkaew P, Lee TJ, Yang MC.

Value Health. 2009 Nov-Dec;12 Suppl 3:S4-11. doi: 10.1111/j.1524-4733.2009.00620.x. Review.

18.

Funding, coverage, and access under Thailand's universal health insurance program: an update after ten years.

Damrongplasit K, Melnick G.

Appl Health Econ Health Policy. 2015 Apr;13(2):157-66. doi: 10.1007/s40258-014-0148-z.

PMID:
25566748
19.

Pharmaceutical policies: effects of financial incentives for prescribers.

Rashidian A, Omidvari AH, Vali Y, Sturm H, Oxman AD.

Cochrane Database Syst Rev. 2015 Aug 4;(8):CD006731. doi: 10.1002/14651858.CD006731.pub2. Review.

PMID:
26239041
20.

Does the market share of generic medicines influence the price level?: a European analysis.

Dylst P, Simoens S.

Pharmacoeconomics. 2011 Oct;29(10):875-82. doi: 10.2165/11585970-000000000-00000.

PMID:
21797288

Supplemental Content

Support Center